Longeveron Inc. Form 8-K Summary
Business Context and Reporting Period
Longeveron Inc. (LGVN), a biotechnology company focused on cell therapy, filed this Current Report on Form 8-K on March 12, 2026, regarding events occurring on March 10 and March 11, 2026. The filing details a private placement financing transaction and the entry into material definitive agreements to secure capital for the clinical development of its lead candidate, laromestrocel, for Hypoplastic Left Heart Syndrome (HLHS).
Key Financial Metrics and Transaction Details
- Initial Closing Proceeds: Approximately $15.9 million in gross proceeds (before fees and expenses).
- Securities Issued (Initial Closing):
- 6,013,384 shares of Class A Common Stock at $0.52 per share.
- 11,873.04 shares of Series A Non-Voting Convertible Preferred Stock at $1,000.00 per share (convertible into 22,832,770 shares of Common Stock).
- Placement Agent Fees: 7.0% cash fee plus 1.0% management fee of gross proceeds, plus expense reimbursement.
- Placement Agent Warrants: Issued to designees of H.C. Wainwright & Co., LLC to purchase up to 2,019,231 shares at an exercise price of $0.65 per share (125% of the share price), exercisable immediately with a 5-year term.
- Pro Forma Share Count: Approximately 54,133,139 shares of Common Stock outstanding on a fully diluted basis (including conversion of Preferred Stock and exercise of warrants).
- Liquidity Outlook: Management expects existing cash and net proceeds to fund operations into the fourth quarter of 2026, excluding potential proceeds from a Second Closing.
Material Changes and Agreements
The filing reports the execution of a Securities Purchase Agreement and a Registration Rights Agreement. A unique feature of this transaction is the sale of a 50% interest in the proceeds from a potential future Rare Pediatric Disease Priority Review Voucher (PRV) to be received from the FDA for the HLHS program.
Second Closing Conditions: The Company agreed to a potential second closing for approximately $15.0 million in additional gross proceeds, contingent upon:
- Milestone: Announcement of Phase 2b study results for HLHS demonstrating statistical significance of primary endpoints.
- Price Threshold: A volume-weighted average price (VWAP) of at least $1.85 per share with aggregate trading volume of at least 25,000,000 shares over any ten consecutive trading days within 30 days of the Milestone announcement.
Lock-Up Provisions: The Company is prohibited for 90 days post-closing from issuing new equity or filing registration statements without investor consent. For an additional 90 days thereafter, the Company cannot sell shares via its "at-the-market" facility at a price below $0.80 per share without consent from holders of 50.1% of the Initial Closing securities.
Guidance, Risks, and Management Commentary
Management intends to use net proceeds for ongoing clinical and regulatory development of laromestrocel, working capital, and general corporate purposes. The filing includes extensive forward-looking statements regarding the success of clinical trials, the receipt of the PRV, and the ability to achieve the milestones required for the Second Closing.
Key Risks Disclosed:
- Failure to achieve the clinical milestone or price threshold required for the Second Closing.
- Dilution to existing shareholders due to the issuance of Common Stock and convertible Preferred Stock.
- Uncertainty regarding the timing and receipt of the Priority Review Voucher.
- Reliance on the ability to raise additional capital if the Second Closing does not occur or if cash burn exceeds expectations.
Investor Verification Checklist
- Verify the exact net proceeds received after deducting the 8% total placement agent fees and other transaction expenses.
- Confirm the specific terms of the 50% interest sale in the potential Priority Review Voucher proceeds.
- Monitor the Phase 2b study timeline for HLHS to assess the likelihood of triggering the Second Closing.
- Review the Certificate of Designation (Exhibit 3.1) for specific limitations on the conversion of Series A Preferred Stock (e.g., the 4.99% beneficial ownership limit).
- Assess the impact of the 90-day lock-up and the $0.80 price floor on the Company's ability to raise capital via its ATM facility in the near term.